Black Diamond Therapeutics Inc (NASDAQ:BDTX) price on Thursday, March 28, rose 3.47% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $5.07.
A look at the stock’s price movement, the close in the last trading session was $4.90. The beta value (5-Year monthly) was 2.65. Turning to its 52-week performance, $6.85 and $1.43 were the 52-week high and 52-week low respectively. Overall, BDTX moved 2.42% over the past month.
Black Diamond Therapeutics Inc’s market cap currently stands at around $262.22 million, with investors looking forward to this quarter’s earnings report slated for May 07, 2024 – May 13, 2024. Analysts project the company’s earnings per share (EPS) to be -$0.43, which has seen fiscal year 2024 EPS growth forecast to increase to -$1.73 and about -$1.94 for fiscal year 2025. Per the data, EPS growth is expected to be 8.00% for 2024 and -12.10% for the next financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was 1 upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that BDTX is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
BDTX’s current price about 8.90% and 19.51% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 56.40, while 7-day volatility ratio is 8.65% and 8.80% in the 30-day chart. Further, Black Diamond Therapeutics Inc (BDTX) has a beta value of 2.64, and an average true range (ATR) of 0.43.
If we refocus on Black Diamond Therapeutics Inc (NASDAQ:BDTX), historical trading data shows that trading volumes averaged 0.6 million over the past 10 days and 600.99K over the past 3 months. The company’s latest data on shares outstanding shows there are 51.65 million shares.
The 26.30% of Black Diamond Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 69.42% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.81 million on Mar 15, 2024, giving us a short ratio of 2.78. The data shows that as of Mar 15, 2024 short interest in Black Diamond Therapeutics Inc (BDTX) stood at 3.50% of shares outstanding, with shares short falling to 1.88 million registered in Feb 15, 2024. Current price change has pushed the stock 80.43% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BDTX stock continues to rise going into the next quarter.